Article: Leveraging GMP Release and Stability Testing Methods

This new article from Coriolis Pharma underscores the critical role of GMP-compliant analytical testing in ensuring drug quality and stability. It highlights the need for specialized methods to manage complexity, support regulatory compliance, and safeguard product integrity throughout development.

Ensuring the quality and stability of drug products requires rigorous analytical testing throughout the development life cycle. By leveraging Good Manufacturing Practice (GMP)-compliant analytical methods — both standardized and customized — biopharma companies can mitigate risks, maintain regulatory compliance, and accelerate development timelines. As drug modalities become increasingly complex, specialized analytical capabilities are essential for ensuring consistency and accuracy of data, as well as long-term product integrity.

Assuring Quality and Safety across the Product Life CycleRelease and stability testing are fundamental to maintaining the quality and safety of drug products. To ensure that these standards are met, analytical methods must be carefully developed, validated, and conducted in accordance with Good Manufacturing Practice (GMP) requirements. These methods provide the necessary assurance that drug products remain safe, effective, and compliant throughout their entire life cycle.

Release testing confirms that drug substances and drug products meet defined specifications immediately following manufacturing. Stability studies, on the other hand, assess whether product quality is maintained over time, ensuring consistent efficacy and safety during product shelf-life. When conducted in a GMP environment, these tests rely on validated methods, qualified equipment, and trained personnel, guaranteeing the reliability of analytical results.

The complexity of maintaining quality across a drug’s life cycle is underscored by the need for analytical life cycle management. A drug product may remain on the market for 15 years or longer, requiring the analytical methods to deliver accurate, robust, and consistent results over time. This challenge is further compounded by inevitable changes — whether in manufacturing processes, regulatory requirements, or analytical technologies. Analytical service providers must be flexible and able to allow seamless adaptation of GMP methods to evolving requirements while maintaining data integrity and comparability.

A critical aspect of GMP analytics is its role in detecting trends in product quality that may emerge across multiple production batches. Small, incremental variations may not be immediately relevant for product quality or safety but can become significant when assessed across multiple production cycles, as they indicate drifts in the manufacturing processes. A well characterized product and reference standard are of crucial importance for evaluation of such changes. By implementing finely tuned and robust analytical controls, companies can identify trends early and proactively address potential risks.

At Coriolis Pharma, we prioritize the integration of appropriate methods early in the development process, aligning them with formulation efforts to ensure a seamless transition from preclinical studies through commercialization. We aim to start with working on “qualified equipment” and to develop robust analytical methods that can further on be GMP-controlled and validated to support drug development from first-in-human trials through late-stage clinical phases, process performance qualification (PPQ), and commercial supply. By establishing high-quality, GMP-compliant methods early, we help ensure data continuity, regulatory compliance, and long-term product stability.